Burlington, MA, USA– 25th November 2019 – Sekisui Diagnostics’ Enzyme business unveiled its new Bioprocess Innovation Centre at its site near Maidstone, Kent, UK. The new R&D facility, costing [...]
Click here for full story
Burlington, MA – October 8, 2019 –Sekisui Diagnostics announces the Acucy Influenza A&B Test has received 510(k) clearance as a Class II assay from the US Food and Drug [...]
Sekisui Diagnostics, LLC announces today the launch of the Silaris RSV Test, the newest assay on their molecular, point-of-care (POC) system. Silaris is an affordable, CLIA Waived, polymerase chain [...]
As of June 26, 2019, Sekisui Diagnostics global headquarters has relocated to One Wall Street, Burlington, MA. One Wall Street houses 14 companies and features a fitness center and [...]
Lexington, MA, USA – May 14, 2019 – Sekisui Diagnostics Enzyme business announces the completion of a new BioProcess Innovation Centre at the site in Maidstone, Kent by the [...]
The FastPack® IP SHBG is a chemiluminescent immunoassay intended for the quantitative determination of Sex Hormone Binding Globulin in human serum and plasma on the FastPack® System. Testosterone is the primary [...]
Sekisui Diagnostics in Charlottetown is expanding again to add capacity and jobs which will benefit Islanders and the province’s economy.
Sekisui Diagnostics PEI named Canada's Top 100 Employers for second year in a row.
Lexington, MA – July 30, 2018 – Sekisui Diagnostics announces the FDA clearance of their SEKURE® HbA1c assay. The assay has been cleared to be used as an aid [...]
Expansion could mean more jobs at Charlottetown plant